LX211

DRUG4 trials

Sponsors

Lux Biosciences, Inc.

Conditions

Noninfectious UveitisPanuveitisUveitis, AnteriorUveitis, IntermediateUveitis, Posterior

Phase 3

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

CompletedNCT00404612

Lux Biosciences, Inc.Panuveitis, Uveitis, Intermediate, Uveitis, Posterior

Start: 2007-01-31End: 2009-05-31Updated: 2012-10-11

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

CompletedNCT00404885

Lux Biosciences, Inc.Panuveitis, Uveitis, Anterior

Start: 2007-01-31End: 2009-05-31Updated: 2012-06-22

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

CompletedNCT00404742

Lux Biosciences, Inc.Panuveitis, Uveitis, Intermediate, Uveitis, Posterior

Start: 2007-01-31End: 2009-05-31Updated: 2012-06-22

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

CompletedNCT01243983

Lux Biosciences, Inc.Noninfectious Uveitis

Start: 2011-02-28End: 2012-12-31Updated: 2013-01-10